Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Internal Med
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Internal Med
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
etanercept  etanercept
hypertension  hypertension
chf  chf
antiphospholipid  antiphospholipid
fibrosis  fibrosis
mrsa  mrsa
scid  scid
renal cell  renal cell
rickets  rickets
counterpulsation  counterpulsation
 
Sponsor
etanercept

Top etanercept Articles in Internal Medicine

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Canadian Medical Association Journal, 11/24/2009
with adalimumab and etanercept. Adalimumab, anakinra and infliximab were more likely than etanercept to lead to withdrawals related to adverse events. Given the limitations of indirect comparisons, anakinra was less effective than adalimumab and etanercept, and etanercept was safer than adalimumab [more...]

Pretreatment With the Tumor Nerosis Factor-[alpha] Blocker Etanercept Attenuated Ischemia-Reperfusion Renal Injury
Transplantation Proceedings, 11/18/2009
Choi DE et al. – Etanercept improved resistance to renal injury during IR by enhancing the activation of ERK and increasing the Bcl–2/Bax ratio. [more...]

Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
Journal of Dermatological Treatment, 12/07/2009
Mazzotta A et al. – Etanercept is a safe and effective agent in the long–term management of PsA patients. After 3 years of continuous treatment, symptoms were under control in the ... was a low level of disease activity. [more...]

Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis
Scandinavian Journal of Rheumatology, 11/19/2009
Klimiuk PA et al. – The study shows that, besides a rapid suppression of disease activity, serum sCAM and ... concentrations are downregulated following anti–tumour necrosis factor alpha therapy combined with MTX. Prolonged treatment with etanercept sustained or even more remarkably diminished the sCAM and VEGF serum concentrations. [more...]

Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation
Journal of the European Academy of Dermatology and Venereology, 11/23/2009
Martyn–Simmons CL et al. – Initial data from this open–label prospective evaluation suggests that weekly adalimumab therapy is an effective treatment for patients with severe ... high–dosage etanercept. [more...]

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study
Journal of the European Academy of Dermatology and Venereology, 11/18/2009
Dauden E et al. – At baseline, patients exhibited significant quality–of–life impairment. Both continuous and paused etanercept treatment provided improvements in PRO measures. Either [more...]

Early subcutaneous administration of etanercept (ENBREL) prevents from hyperoxia-induced lung injury
Experimental Lung Research, 11/09/2009
Guthmann F et al. – The authors assume that subcutaneous administration of etanercept might be suitable to prevent acute lung injury and its sequelae induced by hyperoxic ventilation of [more...]

Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis
Modern Rheumatology, 11/25/2009
Tsujimura S et al. – Etanercept is useful for overcoming P-gp-mediated treatment resistance in intractable RA patients who have to discontinue infliximab or are intolerant ... CD69.
  • Incubation of these lymphocytes with dexamethasone in vitro reduced intracellular dexamethasone levels.
  • Two-week etanercept therapy significantly reduced P-gp expression and eliminated such P-gp- and CD69-high-expressing subgroup.
  • The reduction in P-gp resulted in [more...]
  • Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis
    Rheumatology, 11/23/2009
    in patients with RA.

    Methods

    • Large cohort of Caucasian RA patients treated with anti-TNF medications (total, n = 1050; etanercept, n = 455; infliximab, n = 450; and adalimumab, n = 142), sIL-6R A358C polymorphism genotyped using Taqman 5'-allelic discrimination assay
    • [more...]

    Repair of erosions occurs almost exclusively in damaged joints without swelling
    Annals of Rheumatic Diseases, 11/12/2009
    Lukas C et al. – Repair of erosions almost exclusively occurs in joints with improvement or absence of swelling, in patients treated with etanercept. Progression is seen more frequently in joints with persistent swelling, in patients receiving methotrexate monotherapy, primarily if damage is [more...]

    Sponsor

    Read a Different Specialty

    Allergy/Immunology
    Anesthesiology
    Cardiology
    Dermatology
    Drugs
    Emergency Medicine
    Endocrinology
    ENT
    Family Medicine
    Gastroenterology
    Hematology-Oncology
    Infectious Disease
    Internal Medicine
    Nephrology
    Neurology
    OB/Gyn
    Ophthalmology
    Orthopedics
    Pain
    Pediatrics
    Practice Management
    Psychiatry
    Pulmonology
    Radiology
    Rheumatology
    Surgery
    Urology

    General Internal Medical Articles: Profession Index

    Dentist
    Hospital Administrator
    Nurse
        Medical Students
    Nurse Practitioner
    Pharma/Drug Marketer
        Pharmacist
    Physician Assistants
    Article Search
    Keyword:
    Search:
    Published within:
    Sort By:
    Date Relevance
        
    Sponsor
    Sponsor
    About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

    English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

    ©1999-2009 MDLinx, Inc.